

Tautomerism in 2-ketomethylquinolineazines

Hossein Loghmani-Khouzani^{a,*}, Alireza Minaeifar^a, Ryszard Gawinecki^b

^a Department of Chemistry, University of Isfahan, Isfahan 81746-73441, Iran

^b Department of Chemistry, University of Technology and Life Sciences, Seminaryjna 3, PL-85-326 Bydgoszcz, Poland

H I G H L I G H T S

- ▶ Structure of a new series 2-ketomethylquinolineazines and identification of their tautomeric forms.
- ▶ Strength intramolecular hydrogen bonding.
- ▶ Different tautomers to be present in solutions.
- ▶ Tautomerism.
- ▶ Azines.

A R T I C L E I N F O

Article history:

Received 20 February 2012

Received in revised form 14 May 2012

Accepted 14 May 2012

Available online 29 May 2012

Keywords:

2-Ketomethylquinolines

2-Ketomethylquinolinehydrazones

Azines

Tautomerism

A B S T R A C T

A series of new azines were prepared in three steps. Structures of all compounds have been elucidated using spectroscopic methods and elemental analysis. Our studies show that in chloroform solution generally two tautomeric forms are in equilibrium. In some cases, one tautomer was the dominant species.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

Azines are a class of compounds that undergo a wide variety of chemical processes and have interesting chemical properties. These compounds are also valuable intermediates for synthesis of heterocyclic compounds [1], show biological activities including antibacterial [2], antifungal [3] and antitumor [4], form complexes with transition metals [5], and are used as nonlinear optical materials [6] and in designing of liquid crystals [7].

2. Experimental

Melting points were obtained by a Stuart Scientific SMP2 apparatus and are uncorrected. Yields refer to the isolated products and all products were characterized by their physical and spectral data. IR spectra were recorded on IR-435 Shimadzu spectrophotometer. ¹H and ¹³C NMR (500 and 125 MHz) spectra were recorded on a Bruker-Avance AQS 500 spectrometer in CDCl₃ and tetramethylsil-


ane (TMS) as an internal standard. Mass spectra were obtained on GC/MS/DS Varient-Sinngan spectrometer (EI mode at 70 eV). Elemental analysis was done on CHN-O-RAPID, Heraeus CHNS. UV–VIS spectra were recorded on Shimadzu UV-160 spectrophotometer. All 2-ketomethylquinolines were characterized by comparison of their spectroscopic data (IR, ¹H NMR) and melting points with those of reported in the literature [8].

2.1. General procedure for synthesis of symmetrical 2-ketomethylquinolineazine (3a)

2-Ketoiminomethylquinolines **1a–1b**, Scheme 2 were prepared by following Rousel [8c] literature method. **1a** was later used in preparation of symmetrical azines **3a**. 2-Ketoiminomethylquinoline (**1a**) (2.0 mmol) was dissolved in the minimum amount of ethanol and a drop of acetic acid and hydrazine monohydrate (1.0 mmol) was added. Content of the reaction vessel was stirred vigorously at 80 °C for 30 min. The reaction mixture was then cooled and the white solid formed separated by filtration. The crude product was purified by crystallization from ethanol.

* Corresponding author. Tel.: +98 3116687411; fax: +98 3116689732.

E-mail address: loghmani_sh@hotmail.com (H. Loghmani-Khouzani).



Scheme 1. Synthesis of 2-ketomethylquinolineazines.

2.2. (Z)-3,3-Dimethyl-1-(quinolin-2(1H)-ylidene)butan-2-imine (**1a**)

White needles; mp 100–102 °C; IR (KBr) ν : 3410, 1625, 1590, 1530 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 1.2 (s, 9H, CH_3), 5.2 (s, 1H, CH), 6.8–8.00 (m, 8H, $\text{C}_9\text{H}_6\text{N}$ and 2NH).

2.3. 1-Phenyl-2-(quinolin-2-yl)ethanimine (**1b**)

White needles; mp 152–154 °C; IR (KBr) ν : 3340, 1615, 1585, 1530 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 5.8 (s, 1H, CH), 6.5–8.0 (m, 13H, $\text{C}_9\text{H}_6\text{N}$, C_6H_5 and 2NH), 6.5 (broad, 2H, 2NH).

2.4. (1Z,2Z)-1,2-bis(3,3-Dimethyl-1-(quinolin-2-yl)butan-2-ylidene)hydrazine (**3a**)

White needles; mp 174–176 °C; UV (nm) in chloroform: 317.0, 303.5, 278.5; IR (KBr) ν : 1615, 1590, 1570, 1555, 1500 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 1.03 (s, 18H, CH_3), 4.27 (s, 4H, CH_2), 7.44–8.12(m, 12H, Ar–H). ^{13}C NMR (125 MHz, CDCl_3): 28.5 (CH_3), 38.2 (C), 39.6 (CH_2), 122.0, 126.1, 127.1, 127.8, 129.3, 129.6, 136.3, 148.3, 159.5, 165.5, 169.8 (Ar–C); MS (EI, 70 eV) m/z (%): 450 [M]⁺, 393, 337, 225, 169, 143 (100%), 128, 57. Anal. Calcd. For $\text{C}_{30}\text{H}_{34}\text{N}_4$: C, 79.96; H, 7.60; N, 12.43. Found: C, 79.46; H, 7.41; N, 12.30.

2.5. General procedure for synthesis of 2-ketomethylquinolinehydrazones (2a–2d)

2-Ketomethylquinoline (1.0 mmol) was dissolved in the minimum amount of ethanol and a drop of acetic acid and hydrazine monohydrate (2.0 mmol) was added. The mixture was stirred vigorously at 80 °C for about 6 h. Progress of the reaction was followed by TLC (eluent:ethyl acetate/petroleum ether, 1:5). After completion of reaction the mixture was cooled and the solid formed separated by filtration. The crude product was purified by crystallization from ethanol.

2.6. (Z)-2-(2-Hydrazono-2-phenylethyl)quinoline (**2a**)

White needles; mp 121–123 °C; IR (KBr) ν : 3340, 3135, 1630, 1614, 1595 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 4.30 (s, 2H, CH_2), 6.5 (broad, 2H, NH_2). 7.0–8.5 (m, 11H, $\text{C}_9\text{H}_6\text{N}$, C_6H_5).

2.7. (Z)-2-(2-Hydrazono-2-*p*-tolylethyl)quinoline (**2b**)

White needles; mp 105–107 °C; IR (KBr) ν : 3360, 3130, 1645, 1600, 1590 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 2.3 (s, 3H, CH_3), 4.2 (s, 2H, CH_2), 6.5 (broad, 2H, NH_2), 7.0–8.2 (m, 10H, $\text{C}_9\text{H}_6\text{N}$, *p*- C_6H_4).

2.8. (Z)-2-(2-Hydrazono-2-(4-methoxyphenyl)ethyl)quinoline (**2c**)


White needles; mp 152–154 °C; IR (KBr) ν : 3365, 3130, 1635, 1605, 1590 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 3.8 (s, 3H, OCH_3), 4.8 (s, 2H, CH_2), 6.5 (broad, 2H, NH_2), 6.5–8.5 (m, 10H, $\text{C}_9\text{H}_6\text{N}$, *p*- C_6H_4).

2.9. (Z)-2-(2-Hydrazono-3,3-dimethylbutyl)quinoline (**2d**)

White needles; mp 105–107 °C; IR (KBr) ν : 3320, 3205, 1640, 1620, 1595 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 1.1 (s, 9H, CH_3), 4.0 (s, 2H, CH_2), 6.2 (broad, 2H, NH_2), 7.0–8.2 (m, 6H, $\text{C}_9\text{H}_6\text{N}$).


2.10. General procedure for synthesis of unsymmetrical 2-ketomethyl quinolineazines

2-Ketomethylquinolinehydrazone (2.0 mmol) was dissolved in the minimum amount of ethanol and a drop of acetic acid and aldehyde or ketone (2.0 mmol) was added. The mixture was stirred vigorously at 80 °C for the appropriate times (Table 1). Progress of the reaction was followed by TLC (eluent:ethyl acetate/petroleum ether, 1:5). After completion of reaction the mixture was cooled and the solid formed separated by filtration. The crude product was purified by crystallization from ethanol.



Scheme 2. Synthesis of symmetrical azine.

Table 1
The 2-ketomethylquinolineazines synthesized in this work.



| Com. | R ¹ | R ² | R ³ | mp (C) | Reaction times (min) | Yield (%) |
|-----------|----------------|----------------|-------------------------------------|---------|----------------------|-----------|
| 3a | <i>t</i> -Bu | <i>t</i> -Bu | CH ₂ (2-Q ^a) | 174–176 | 360 | 70 |
| 3b | Ph | Me | Ph | 148–150 | 360 | 75 |
| 3c | <i>p</i> -MePh | Me | Ph | 133–135 | 360 | 75 |
| 3d | Ph | H | Ph | 127–129 | 360 | 75 |
| 3e | <i>p</i> -MePh | H | Ph | 160–162 | 360 | 75 |
| 3f | Ph | H | <i>p</i> -NO ₂ Ph | 186–188 | 30 | 90 |
| 3g | <i>p</i> -MePh | H | <i>p</i> -NO ₂ Ph | 187–189 | 30 | 90 |
| 3h | <i>t</i> -Bu | H | <i>p</i> -NO ₂ Ph | 163–165 | 30 | 90 |
| 3i | <i>p</i> -MePh | Me | <i>p</i> -BrPh | 131–133 | 300 | 85 |
| 3j | Ph | Me | <i>p</i> -BrPh | 160–162 | 300 | 85 |
| 3k | <i>t</i> -Bu | Me | <i>p</i> -BrPh | 113–115 | 300 | 80 |
| 3l | Ph | H | <i>p</i> -ClPh | 138–140 | 300 | 85 |
| 3m | <i>p</i> -MePh | H | <i>p</i> -ClPh | 193–195 | 300 | 85 |
| 3n | Ph | H | <i>o</i> -NO ₂ Ph | 201–203 | 300 | 90 |
| 3o | <i>p</i> -MePh | H | <i>o</i> -NO ₂ Ph | 184–186 | 30 | 90 |
| 3p | <i>t</i> -Bu | H | <i>o</i> -NO ₂ Ph | 155–157 | 30 | 90 |
| 3q | Ph | H | <i>m</i> -NO ₂ Ph | 162–164 | 30 | 90 |
| 3r | <i>p</i> -MePh | H | <i>m</i> -NO ₂ Ph | 167–169 | 30 | 90 |
| 3s | <i>t</i> -Bu | H | <i>m</i> -NO ₂ Ph | 129–131 | 30 | 90 |

^a Quinolinyli.

2.11. 2-((Z)-2-Phenyl-2-((Z)-2-(1-phenyllidene)hydrazinyl)vinyl)quinoline (**3b**)

White needles; mp 148–150 °C; UV (nm) in chloroform; 433, 300, 300; IR (KBr) ν : 3250, 1620, 1595, 1550, 1505 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.64 (s, 3H, CH₃), 5.55 (s, 1H, CH), 7.16–7.92 (m, 16H, Ar–H), 13.94 (s, 1H, NH). ¹³C NMR (125 MHz, CDCl₃): 14.3 (CH₃), 98.7 (CH), 123.1, 124.5, 125.2, 125.7, 125.9, 126.8, 126.9, 127.7, 127.8, 128.1, 128.4, 128.5, 128.5, 129.6, 129.7, 136.8, 138.9, 143.9, 147.1, 153.1, 158.3, 158.9 (Ar–C); MS (EI, 70 eV) m/z (%): 363 [M]⁺, 348, 245, 230, 221, 169, 156, 143, 128, 118, 103, 91, 77 (100%), 57. Anal. Calcd. For C₂₅H₂₁N₃: C, 81.61; H, 5.82; N, 11.56. Found: C, 81.11; H, 5.84; N, 11.30.

2.12. 2-((Z)-2-((Z)-2-(1-Phenylethylidene)hydrazinyl)-2-*p*-tolylvinyl)quinoline (**3c**)

White needles; mp 133–135 °C; UV (nm) in chloroform; 437, 300; IR (KBr) ν : 3300, 1620, 1590, 1550, 1500 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.29 (s, 1H, CH₃, tautomer B), 2.33 (s, 2H, CH₃, tautomer A), 2.42 (s, 1H, CH₃, tautomer B), 2.64 (s, 2H, CH₃, tautomer A), 4.71 (s, 1.2H, CH₂), 5.55 (s, 0.4H, CH), 7.15–8.00 (m, 15H, Ar–H), 13.94 (broad, 0.4H, NH). ¹³C NMR (125 MHz, CDCl₃): 14.0 (CH₃), 15.8 (CH₃), 21.5 (CH₃), 21.7 (CH₃), 38.9 (CH₂), 98.4 (CH), 121.2, 123.0, 125.9, 126.7, 126.8, 126.9, 127.4, 127.6, 128.0, 128.4, 129.2, 129.5, 129.7, 134.3, 138.4, 139.0, 140.1, 153.2, 158.5, 158.9, 159.0 (Ar–C); MS (EI, 70 eV) m/z (%): 377 [M]⁺, 362, 244, 235, 169, 156, 143, 128, 104, 77, 44 (100%). Anal. Calcd. For C₂₆H₂₃N₃: C, 82.27; H, 6.14; N, 11.13. Found: C, 82.31; H, 6.12; N, 11.14.

2.13. 2-((Z)-2-((Z)-2-Benzylidenhydrazinyl)-2-phenylvinyl)quinoline (**3d**)

White needles; mp 127–129 °C; UV (nm) in chloroform; 431, 303; IR (KBr) ν : 3200, 1622, 1590, 1560, 1540, 1500 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 5.02 (s, 1.4H, CH₂), 5.55 (s, 0.2H, CH), 7.18–8.20 (m, 17H, Ar–H), 14.95 (s, 0.2H, NH). ¹³C NMR

(125 MHz, CDCl₃): 39.4 (CH₂), 97.0 (CH), 121.5, 126.4, 126.9, 127.9, 128.1, 128.3, 128.8, 128.9, 129.1, 129.2, 129.3, 129.9, 130.7, 131.3, 134.9, 137.1, 137.5, 148.3, 148.7, 160.7, 165.6 (Ar–C); MS (EI, 70 eV) m/z (%): 349 [M]⁺, 245, 230, 221, 169, 156, 143 (100%), 129, 104, 91, 77, 51. Anal. Calcd. For C₂₄H₁₉N₃: C, 81.49; H, 5.48; N, 12.02. Found: C, 81.65; H, 5.48; N, 11.69.

2.14. 2-((Z)-2-((Z)-2-Benzylidenhydrazinyl)-2-*p*-tolylvinyl)quinoline (**3e**)

White needles; mp 160–162 °C; UV (nm) in chloroform; 431, 303; IR (KBr) ν : 3200, 1622, 1590, 1540, 1500 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.37 (s, 1.5H, CH₃), 2.48 (s, 1.5H, CH₃), 4.99 (s, 1.0H, CH₂), 5.55 (s, 0.5H, CH), 7.15–8.20 (m, 15H, Ar–H), 14.55 (s, 0.5H, NH). ¹³C NMR (125 MHz, CDCl₃): 21.8 (CH₃), 21.9 (CH₃), 39.2 (CH₂), 97.8 (CH), 121.5, 122.2, 124.8, 126.9, 127.3, 127.9, 128.2, 128.8, 129.0, 129.6, 129.6, 129.8, 129.9, 131.4, 135.6, 137.0, 140.9, 147.4, 148.4, 158.9, 160.4, 165.6 (Ar–C); MS (EI, 70 eV) m/z (%): 363 [M]⁺, 285, 259, 245, 169, 156, 143 (100%), 118, 104, 91, 77, 44. Anal. Calcd. For C₂₅H₂₁N₃: C, 82.61; H, 5.82; N, 11.46.

2.15. 2-((Z)-2-((Z)-4-Nitrobenzylidene)hydrazinyl)-2-phenylvinyl)quinoline (**3f**)

White needles; mp 186–188 °C; UV (nm) in chloroform; 449, 385, 303, 265.5; IR (KBr) ν : 3200, 1622, 1590, 1540, 1505 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 4.92 (s, 0.3H, CH₂), 5.64 (s, 0.7H, CH), 7.22–8.20 (m, 15H, Ar–H), 14.76 (s, 0.7H, NH). ¹³C NMR (125 MHz, CDCl₃): 39.0 (CH₂), 100.2 (CH), 123.3, 124.4, 125.9, 126.9, 127.4, 128.0, 128.2, 128.9, 129.3, 129.4, 129.7, 130.1, 136.2, 136.3, 137.3, 142.2, 147.2, 147.5, 158.5, 165.0 (Ar–C); MS (EI, 70 eV) m/z (%): 394 [M]⁺, 245, 230, 169, 149, 143 (100%), 129, 104, 77, 57, 44. Anal. Calcd. For C₂₄H₁₈N₄O₂: C, 73.08; H, 4.16; N, 14.20. Found: C, 72.70; H, 4.62; N, 14.17.

2.16. 2-((Z)-2((Z)-4-Nitrobenzylidene)hydrazinyl)-2-p-tolylynylquinoline (**3g**)

White needles; mp 187–189 °C; UV (nm) in chloroform; 451, 386, 312, 300, 266; IR (KBr) ν : 3200, 1622, 1590, 1540, 1505 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 2.37 (s, 0.75H, CH_3), 2.49 (s, 2.25H, CH_3), 4.92 (s, 0.4H, CH_2), 5.55 (s, 0.8H, CH), 7.20–8.25 (m, 14H, Ar–H), 14.78 (s, 0.8H, NH). ^{13}C NMR (125 MHz, CDCl_3): 19.9 (CH_3), 21.8 (CH_3), 39.4 (CH_2), 99.6 (CH), 121.2, 123.3, 124.4, 125.3, 126.9, 127.4, 128.0, 128.4, 128.9, 129.4, 129.6, 130.1, 133.4, 136.1, 137.2, 139.3, 142.3, 147.5, 152.4, 157.3, 158.5 (Ar–C); MS (EI, 70 eV) m/z (%): 408 $[\text{M}]^+$, 244, 149, 156, 143 (100%), 129, 118, 91. Anal. Calcd. For $\text{C}_{25}\text{H}_{20}\text{N}_4\text{O}_2$: C, 73.51; H, 4.94; N, 13.72. Found: C, 73.05; H, 4.98; N, 13.65.

2.17. 2-((Z)-3,3-Dimethyl-2-((Z)-2-(4-nitrobenzylidene)hydrazinyl)but-1-enyl)quinoline (**3h**)

White needles; mp 163–165 °C; UV (nm) in chloroform; 460, 382, 361, 310; IR (KBr) ν : 3200, 1625, 1595, 1520 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 1.31 (s, 6H, CH_3), 1.56 (s, 3H, CH_3), 4.36 (s, 1.4H, CH_2), 5.52 (s, 0.3H, CH), 7.20–8.35 (m, 10H, Ar–H), 15.18 (s, 0.3H, NH). ^{13}C NMR (125 MHz, CDCl_3): 28.2 (CH_3), 29.4 (CH_3), 38.1 (C) 39.0 (CH_2), 94.0 (CH), 120.1, 123.8, 124.3, 127.4, 128.5 (Ar–C); MS (EI, 70 eV) m/z (%): 374 $[\text{M}]^+$, 246, 225, 169, 158, 157, 156, 149, 143 (100%), 103, 76, 69, 57, 44. Anal. Calcd. For $\text{C}_{22}\text{H}_{22}\text{N}_4\text{O}_2$: C, 71.06; H, 5.83; N, 14.38. Found: C, 70.57; H, 5.92; N, 14.96.

2.18. 2-((Z)-2((Z)-2-(1-Bromophenyl)ethylidene)hydrazinyl)-2-phenylvinylquinoline (**3i**)

White needles; mp 131–133 °C; UV (nm) in chloroform; 434, 300; IR (KBr) ν : 3300, 1630, 1595, 1570, 1560 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 2.36 (s, 2H, CH_3), 2.65 (s, 1H, CH_3), 4.72 (s, 1.4H, CH_2), 5.63 (s, 0.3H, CH), 7.27–8.13 (m, 15H, Ar–H), 14.08 (broad, 0.3H, NH). ^{13}C NMR (125 MHz, CDCl_3): 14.3(CH_3), 15.7 (CH_3), 39.5 (CH_2), 99.4 (CH), 121.5, 126.4, 127.2, 127.6, 127.9, 128.0, 128.1, 128.7, 129.3, 129.9, 130.3, 131.8, 131.9, 136.9, 147.4, 148.4, 158.5, 159.6, 159.7 (Ar–C); MS (EI, 70 eV) m/z (%): 443 $[\text{M}]^+$, 441, 301, 299, 245, 230, 198, 196, 157, 156, 143 (100%), 103, 77, 51, 44. Anal. Calcd. For $\text{C}_{25}\text{H}_{20}\text{N}_3\text{Br}$: C, 67.88; H, 4.56; N, 9.5. Found: C, 67.46; H, 6.64; N, 9.43.

2.19. 2-((Z)-2((Z)-2-(1-Bromophenyl)ethylidene)hydrazinyl)-2-p-tolylynylquinoline (**3j**)

White needles; mp 160–162 °C; UV (nm) in chloroform; 437, 300; IR (KBr) ν : 3300, 1625, 1590, 1540, 1500 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 2.37 (s, 2H, CH_3), 2.38 (s, 1H, CH_3), 2.48 (s, 2H, CH_3), 2.59 (s, 1H, CH_3), 4.72 (s, 1.4H, CH_2), 5.62 (s, 0.3H, CH), 7.22–8.0 (m, 14H, Ar–H), 14.08 (broad, 0.3H, NH). ^{13}C NMR (125 MHz, CDCl_3): 14.9 (CH_3), 15.7 (CH_3), 20.0 (CH_3), 22.1 (CH_3), 39.0 (CH_2), 98.0 (CH), 121.48, 126.4, 127.2, 127.6, 127.9, 128.0, 128.1, 128.7, 129.3, 129.8, 130.3, 131.8, 131.9, 136.9, 147.4, 148.4, 158.5, 159.6, 159.7, 160.1, 167.5, 169.7 (Ar–C); MS (EI, 70 eV) m/z (%): 457 $[\text{M}]^+$, 455, 315, 313, 198, 196, 157, 156, 155, 143 (100%), 44. Anal. Calcd. For $\text{C}_{26}\text{H}_{22}\text{N}_3\text{Br}$: C, 68.43; H, 4.86; N, 9.21. Found: C, 68.49; H, 4.19; N, 9.20.

2.20. 2-((Z)-2((Z)-2-(1-(4-Bromophenyl)ethylidene)hydrazinyl)-3,3-dimethylbut-1-enyl)quinoline (**3k**)

White needles; mp 113–115 °C; UV (nm) in chloroform; 442, 335, 323, 300; IR (KBr) ν : 3200, 1630, 1600, 1540 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 1.31 (s, 4H, CH_3), 1.61(s, 5H, CH_3), 2.19 (s,

1.3H, CH_3), 2.32(s, 1.7H, CH_3), 4.19 (s, 0.8H, CH_2), 5.52 (s, 0.6H, CH), 7.20–8.05 (m, 10H, Ar–H), 15.18 (s, 0.6H, NH). ^{13}C NMR (125 MHz, CDCl_3): 15.2 (CH_3), 15.3 (CH_3), 28.9 (CH_3), 30.1(CH_3), 36.7 (C), 38.6 (C), 39.7 (CH_2), 94.0 (CH), 120.1, 123.8, 124.3, 127.4, 128.5, 159.2, 165.8 (Ar–C); MS (EI, 70 eV) m/z (%): 374 $[\text{M}]^+$, 246, 225, 169, 149, 156, 143 (100%), 103, 76, 69, 57, 44. Anal. Calcd. For $\text{C}_{22}\text{H}_{22}\text{N}_4\text{O}_2$: C, 71.06; H, 5.83; N, 14.38. Found: C, 70.57; H, 5.92; N, 14.96.

2.21. 2-((Z)-2-((E)-(4-Chlorobenzylidene)hydrazono)-2-phenylethyl)quinoline (**3l**)

White needles; mp 138–140 °C; UV (nm) in chloroform; 311, 303; IR (KBr) ν : 1615, 1595, 1560, 1530, 1500 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 4.99 (s, 2H, CH_2), 7.30–8.17 (m, 15H, Ar–H). ^{13}C NMR (125 MHz, CDCl_3): 39.4 (CH_2), 121.4, 126.4, 127.2, 127.9, 128.3, 128.9, 129.4, 129.5, 129.9, 130.1, 130.8, 133.4, 137.1, 137.4, 138.5, 158.6, 159.2, 165.8 (Ar–C); MS (EI, 70 eV) m/z (%): 385 $[\text{M} + 2]^+$, 383 $[\text{M}]^+$, 245, 230, 169, 143 (100%), 104, 77, 51. Anal. Calcd. For $\text{C}_{24}\text{H}_{18}\text{N}_3\text{Cl}$: C, 75.01; H, 4.73; N, 10.95. Found: C, 74.96; H, 4.75; N, 10.92.

2.22. 2-((Z)-2-((E)-(4-Chlorobenzylidene)hydrazono)-2-p-tolylythyl)quinoline (**3m**)

White needles; mp 194–196 °C; UV (nm) in chloroform; 313, 300; IR (KBr) ν : 1622, 1585, 1570, 1550 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 2.36 (s, 3H, CH_3), 4.93 (s, 2H, CH_2), 7.20–8.10 (m, 14H, Ar–H). ^{13}C NMR (125 MHz, CDCl_3): 21.8 (CH_3), 39.4 (CH_2), 121.4, 126.4, 127.2, 127.9, 128.3, 128.9, 129.4, 129.5, 129.9, 130.1, 130.8, 133.4, 137.1, 137.4, 138.5, 158.9, 159.2, 165.8 (Ar–C); MS (EI, 70 eV) m/z (%): 399 $[\text{M} + 2]^+$, 397 $[\text{M}]^+$, 169, 143 (100%), 115, 69, 44. Anal. Calcd. For $\text{C}_{25}\text{H}_{20}\text{N}_3\text{Cl}$: C, 75.46; H, 5.07; N, 10.56. Found: C, 75.96; H, 4.95; N, 10.95.

2.23. 2-((Z)-2((Z)-2-(2-(4-Nitrobenzylidene)hydrazinyl)-2-phenylvinyl)quinoline (**3n**)

White needles; mp 201–203 °C; UV (nm) in chloroform; 440, 401, 303; IR (KBr) ν : 3300, 1622, 1590, 1570, 1540, 1510 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 4.90 (s, 0.14H, CH_2), 5.60 (s, 0.93H, CH), 7.21–8.70 (m, 15H, Ar–H), 14.84 (s, 0.93H, NH). ^{13}C NMR (125 MHz, CDCl_3): 39.0 (CH_2), 100.0 (CH), 123.1, 125.2, 125.5, 125.8, 127.6, 127.8, 128.1, 128.7, 129.1, 129.7, 130.3, 130.9, 133.4, 135.4, 136.1, 136.6, 147.2, 147.6, 152.4, 158.4 (Ar–C); MS (EI, 70 eV) m/z (%): 394 $[\text{M}]^+$, 348, 225, 169, 156, 143 (100%), 103, 46. Anal. Calcd. For $\text{C}_{24}\text{H}_{18}\text{N}_4\text{O}_2$: C, 73.08; H, 4.60; N, 14.10. Found: C, 73.32; H, 4.95; N, 13.58.

2.24. 2-((Z)-2((Z)-2-(4-Nitrobenzylidene)hydrazinyl)-2-p-tolylynyl)quinoline (**3o**)

White needles; mp 184–186 °C; UV (nm) in chloroform; 438, 303; IR (KBr) ν : 3300, 1625, 1590, 1570, 1540, 1510 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 2.37(s, 0.45H, CH_3), 2.48 (s, 2.55H, CH_3), 4.90 (s, 0.28H, CH_2), 5.60 (s, 0.86H, CH), 7.10–8.20 (m, 14H, Ar–H), 14.87 (s, 0.86H, NH). ^{13}C NMR (125 MHz, CDCl_3): 21.8 (CH_3), 39.0 (CH_2), 99.7 (CH), 123.1, 125.2, 125.4, 127.6, 127.8, 128.2, 128.6, 128.9, 129.6, 130.3, 133.4, 136.1, 136.8, 152.2, 158.6. (Ar–C); MS (EI, 70 eV) m/z (%): 408 $[\text{M}]^+$, 362, 225, 169, 156, 143 (100%), 103, 46. Anal. Calcd. For $\text{C}_{24}\text{H}_{18}\text{N}_4\text{O}_2$: C, 73.51; H, 4.94; N, 13.72. Found: C, 72.91; H, 4.72; N, 14.17.

2.25. 2-((Z)-3,3-Dimethyl-2-((Z)-2-(2-nitrobenzylidene)hydrazinyl)but-1-enyl)quinoline (**3p**)

White needles; mp 155–157 °C; UV (nm) in chloroform; 450, 400, 312, 300; IR (KBr) ν : 3300, 1625, 1595, 1570, 1510 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 1.30 (s, 1.8H, CH_3), 1.56 (s, 7.2H, CH_3), 4.38 (s, 0.4H, CH_2), 5.50 (s, 0.8H, CH), 7.16–8.30 (m, 10H, Ar–H), 15.3 (s, 0.8H, NH). ^{13}C NMR (125 MHz, CDCl_3): 28.7 (CH_3), 29.9 (CH_3), 36.5 (C) 38.9 (C), 39.5 (CH_2), 94.8 (CH), 121.3, 123.6, 124.8, 125.2, 125.5, 126.3, 127.4, 127.5, 127.7, 128.3, 130.2, 1314, 133.4, 133.8, 135.8, 147.5, 152.8, 158.6, 158.8, 159.7 (Ar–C); MS (EI, 70 eV) m/z (%): 374 [$\text{M}]^+$, 335, 285, 196, 169, 156, 143 (100%), 128, 91, 77, 51. Anal. Calcd. For $\text{C}_{22}\text{H}_{22}\text{N}_4\text{O}_2$: C, 70.57; H, 5.92; N, 14.96. Found: C, 70.17; H, 5.64; N, 14.49.

2.26. 2-((Z)-2-((Z)-2-(3-Nitrobenzylidene)hydrazinyl)-2-phenylvinyl)quinoline (**3q**)

White needles; mp 162–164 °C; UV (nm) in chloroform; 425, 300; IR (KBr) ν : 3300, 1622, 1580, 1560, 1540 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 4.93 (s, 0.26H, CH_2), 5.60 (s, 0.87H, CH), 7.20–8.32 (m, 15H, Ar–H), 14.70 (broad, 0.87H, NH). ^{13}C NMR (125 MHz, CDCl_3): 39.0 (CH_2), 99.5 (CH), 121.7, 123.1, 123.2, 125.3, 125.8, 127.4, 128.0, 128.2, 129.2, 129.7, 129.8, 130.1, 131.8, 136.1, 137.4, 158.5. (Ar–C); MS (EI, 70 eV) m/z (%): 394 [$\text{M}]^+$, 245, 230, 169, 149, 143 (100%), 104, 77, 44. Anal. Calcd. For $\text{C}_{24}\text{H}_{18}\text{N}_4\text{O}_2$: C, 73.08; H, 4.60; N, 13.20. Found: C, 72.64; H, 4.66; N, 14.06.

2.27. 2-((Z)-2-((Z)-2-(3-Nitrobenzylidene)hydrazinyl)-2-p-tolylylvinyl)quinoline (**3r**)

White needles; mp 167–169 °C; UV (nm) in chloroform; 427, 303; IR (KBr) ν : 3250, 1622, 1580, 1560, 1540 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 2.38 (s, 1H, CH_3), 2.50 (s, 2H, CH_3), 4.96 (s,

0.7H, CH_2), 5.60 (s, 0.65H, CH), 7.20–8.35 (m, 14H, Ar–H), 14.72 (s, 0.65H, NH). ^{13}C NMR (125 MHz, CDCl_3): 21.8 (CH_3), 39.5 (CH_2), 99.0 (CH), 121.7, 123.1, 123.2, 125.2, 127.3, 128.9, 129.6, 130.1, 135.9, 137.4, 154.2, 158.4, 165.2 (Ar–C); MS (EI, 70 eV) m/z (%): 408 [$\text{M}]^+$, 259, 244, 169, 150, 149, 143 (100%), 128, 91, 76, 44. Anal. Calcd. For $\text{C}_{25}\text{H}_{20}\text{N}_4\text{O}_2$: C, 73.51; H, 4.94; N, 13.72. Found: C, 72.98; H, 5.02; N, 13.54.

2.28. 2-((Z)-3,3-Dimethyl-2-((Z)-2-(3-nitrobenzylidene)hydrazinyl)but-1-enyl)quinoline (**3s**)

White needles; mp 129–131 °C; UV (nm) in chloroform; 430, 317, 281; IR (KBr) ν : 3300, 1630, 1600, 1580, 1570, 1550, 1515 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 1.34 (s, 3H, CH_3), 1.57 (s, 6H, CH_3), 4.37 (s, 0.66H, CH_2), 5.47 (s, 0.67H, CH), 7.10–8.40 (m, 10H, Ar–H), 15.10 (broad, 0.67H, NH). ^{13}C NMR (125 MHz, CDCl_3): 28.7 (CH_3), 29.9 (CH_3), 36.6 (C), 38.9 (C), 39.7 (CH_2), 94.2 (CH), 121.3, 121.5, 122.8, 123.9, 125.1, 126.3, 127.3, 127.8, 127.9, 129.3, 129.9, 131.5, 133.7, 133.8, 135.8, 136.6, 147.0, 154.8, 158.9, 160.0, 175.5 (Ar–C); MS (EI, 70 eV) m/z (%): 374 [$\text{M}]^+$, 226, 225, 169, 149, 143 (100%), 128, 57. Anal. Calcd. For $\text{C}_{22}\text{H}_{22}\text{N}_4\text{O}_2$: C, 70.57; H, 5.92; N, 14.97. Found: C, 70.03; H, 5.90; N, 14.97.

3. Results and discussion


New azines studied in the present paper have been synthesized in three steps. At first, a series of 2-ketomethylquinolines have been prepared using literature methods.[8] Tautomerism in this group of compounds have been well worked out by several investigators.[9,10] In the next step 2-ketomethylquinolines in reaction with hydrazine in ethanol solution and a drop of acetic acid as a catalyst were converted to 2-ketomethylquinolinehydrazones (**2a–2d**) in good to high yields (70–95%). Four of these intermediates (Scheme 1, $\text{R}^1 = \text{Ph}$, $p\text{-MeC}_6\text{H}_4$, $p\text{-MeOC}_6\text{H}_4$, Bu^t) were isolated and their structures have been determined by spectroscopic

Table 2
Some ^1H and ^{13}C NMR, UV and IR, data of 2-ketomethylquinolineazines.

| Comp. | ^1H NMR (CDCl_3) (ppm) | | | ^{13}C NMR (CDCl_3) (ppm) | | | | IR (cm^{-1} , KBr disk) | | | UV (nm, in ethanol) | A:B ratio in CDCl_3 |
|-----------|--|---------------|--------------------|---|----------------|-------|----------------|-----------------------------------|------|------|------------------------|------------------------------|
| | CH | CH_2 | NH | CH | CH_2 | C=C | N=C | N–H ^a | C=C | C=N | λ_{max} | |
| 3a | – | 4.27 | – | – | 39.6 | 165.5 | 169.8 | – | 1590 | 1615 | 317 | 100:0 |
| 3b | 5.55 | – | 13.94 | 98.7 | – | 158.3 | 158.9 | 3250 | 1595 | 1620 | 433 | 0:100 |
| 3c | 5.55 | 4.71 | 13.94 | 98.4 | 38.9 | 158.9 | 159.0 | 3300 | 1590 | 1620 | 437 | 66:34 |
| 3d | 5.55 | 5.02 | 14.95 ^a | 97.0 | 39.4 | 160.7 | 165.6 | 3300 | 1590 | 1622 | 431 | 79:21 |
| 3e | 5.55 | 4.99 | 14.55 | 97.8 | 39.2 | 160.4 | 165.6 | 3200 | 1590 | 1622 | 449 | 50:50 |
| 3f | 5.64 | 4.92 | 14.76 | 100.2 | 39.0 | 158.5 | 165.0 | 3200 | 1590 | 1622 | 449 | 35:65 |
| 3g | 5.55 | 4.92 | 14.78 | 99.6 | 39.4 | 157.3 | 158.5 | 3200 | 1590 | 1622 | 451 | 20:80 |
| 3h | 5.52 | 4.36 | 15.18 | 94.0 | 39.0 | 157.0 | 158.0 | 3200 | 1595 | 1625 | 460 | 67:33 |
| 3i | 5.63 | 4.72 | 14.08 | 99.4 | 39.5 | 159.6 | 159.7 | 3300 | 1595 | 1615 | 434 | 63:37 |
| 3j | 5.62 | 4.72 | 14.08 | 98.0 | 39.0 | 167.5 | 169.7 | 3300 | 1590 | 1625 | 437 | 72:28 |
| 3k | 5.52 | 4.19 | 14.08 | 94.0 | 39.7 | 160.6 | 168.8 | 3300 | 1600 | 1630 | 442 | 40:60 |
| 3l | – | 4.99 | – | – | 39.4 | 159.2 | 165.8 | – | 1595 | 1615 | 311 | 100:0 |
| 3m | – | 4.93 | – | – | 39.4 | 158.9 | 165.8 | – | 1585 | 1622 | 313 | 100:0 |
| 3n | 5.60 | 4.90 | 14.84 ^a | 100.0 | – | 158.4 | – | 3300 | 1590 | 1622 | 440 | 7:93 |
| 3o | 5.60 | 4.90 | 14.87 | 99.7 | – ^b | 158.6 | – ^b | 3300 | 1590 | 1625 | 438 | 15:85 |
| 3p | 5.50 | 4.38 | 15.33 | 94.8 | 38.9 | 158.8 | 159.7 | 3300 | 1595 | 1625 | 450 | 19:81 |
| 3q | 5.60 | 4.93 | 14.70 | 99.5 | 39.0 | 158.5 | – | 3300 | 1580 | 1622 | 425 | 13:87 |
| 3r | 5.60 | 4.90 | 14.84 | 99.0 | 39.5 | 162.0 | 165.2 | 3250 | 1580 | 1622 | 427 | 24:76 |
| 3s | 5.47 | 4.37 | 15.10 | 94.2 | 39.7 | 160.0 | 175.5 | 3300 | 1600 | 1630 | 430 | 40:60 |

^a Broad.

^b Not appeared due to low concentration.



Scheme 3. Tautomeric forms for 2-ketomethylquinolines.

methods. Infrared spectra of these compounds (KBr discs) show strong absorption bands around 3360 and 3130 cm^{-1} for —NH_2 of primary amines. The compounds also show a strong absorption around $1645\text{--}1630\text{ cm}^{-1}$ for C=N vibrations.

The ^1H NMR data of these compounds (in chloroform solution) show a broad line at $6.2\text{--}6.5$ ppm for the —NH_2 and another singlet (CH_2) in the aliphatic region around $4.0\text{--}4.8$ ppm. Integrations of these signals confirm there are two protons present in each group. There was no signal around 14.0 ppm corresponding to possible enamine-imine form 2-B (Scheme 1). From these observations we conclude that the 2-ketomethylquinolinehydrazones exist exclusively in the imine form 2-A (Scheme 1).

In the third step 2-ketomethylquinolinehydrazones were treated with different aldehyde and ketone in ethanol solution and in

the presence a drop of acetic acid (as a catalyst) to give unsymmetrical azines (Scheme 1). The reaction, completion time, yield and structure of the compounds are given in Table 1.

For comparison, a symmetrical azine was also prepared via a different route as shown in Scheme 2.

Following our previous work [11], we focused on the structure of a new series of 2-ketomethylquinolineazines, particular by focusing on identification of their tautomers.

UV, IR and NMR spectroscopy were used to determine the structure of the compounds. It was found that this group of compounds could be classified into three main categories, based on their tautomeric forms. Thus, in chloroform solution compounds **3a**, **3l** and **3m** are exclusively in the form 3-A. On the other hand, compound **3b** exist entirely in the form 3-B. Finally derivatives **3c–3k** and **3n–3s** were found to exist as mixtures of both forms (3-A \rightleftharpoons 3-B). The concentration ratio of the two tautomers at equilibrium, A:B (in chloroform solutions) are reported in Table 2.

Typical *cis-s-cis* enaminone C=O and C=C vibrations (KBr disc) for 2-ketomethylquinolines at 1632 and 1585 cm^{-1} have been earlier reported [8].

The infrared data of 2-ketomethylquinolineazines reported in Table 2 show that in the solid state all the compounds were found to be exclusively in the 3-B or 3-C forms. Most of the entries in Table 2 (except **3a**, **3l** and **3m**) show a band around 1620 cm^{-1} for the C=N stretching vibration. Moreover, spectra of these compounds show a broad band around 3300 cm^{-1} for the N—H stretching




Fig. 1. ^1H NMR spectrum of compound **3b** in deuteriochloroform solution.




Fig. 2. ^1H NMR spectrum of compound **3g** in deuteriochloroform solution.

mode. These data correspond to those of the similar azines have been earlier reported.[12] Position of the low field N–H signal in the ^1H NMR spectra is expected to be a measure of the strength of the intramolecular hydrogen bonding.

The IR spectra confirm that in the solid state, the compounds are exclusively in the conjugated forms 3-B or 3-C.

Typical absorption UV band λ_{max} (nm) in ethanol for 2-ketomethylquinolines ($R = \text{Ph}$) has been observed at 459 nm.[13] The UV spectral absorption data of the azines in chloroform solution are given in Table 2. These data show two types of absorption bands. For compounds **3a**, **3l** and **3m**, these absorption bands are located at 317, 311 and 313 nm, respectively (conjugation does not extend on the side and quinoline ring). Thus, only the form 3-A is present there. On the other hand, in the spectra of the other compounds studied, these absorption bands are observed around 425–460 nm which show that conjugation between the side chain and quinoline ring does take place, so they may be in the form 3-B or 3-C.

The ^1H NMR data of the azines studied are presented in Table 2. Typical ^1H NMR lines of the CH_2 and CH groups of the corresponding 2-ketomethylquinolines in chloroform solution have been reported at δ 4.04–4.75 ppm.[8] These ^1H NMR data of the azines are presented in Table 2. These ^1H NMR data for compounds **3a**, **3l** and **3m** in chloroform show a singlet at δ 4.27, 4.99 and 4.93 ppm, respectively. Integration of these signals was exactly proportional to two protons and there was no other signal for the vinylic proton and the N–H proton due to the formation of the second tautomeric forms 3-B or 3-C. There is a singlet corresponding to the vinylic proton at δ 5.55 in which this signal integrated to one proton only, the methylene protons is missing.

Moreover, existence of the forms 3-B or 3-C is proved by the N–H signal at δ 13.94 which arises as a result of strong intramolecular hydrogen bonding between N–H proton and nitrogen in both forms. Tautomeric forms were also observed for the other **3c–3k** and **3n–3s** compounds. Tautomeric ratios were calculated for these compounds from the relative integrals of the signals of vinylic proton and methylene protons. These compounds also revealed broad downfield signals due to the N–H proton around δ 13.94–15.33 of the conjugated form 3-B or 3-C. It should be mentioned that the two doublets in the 6.7–7.9 and 7.6–8.1 ppm regions ($\text{C}_3\text{--H}$ and $\text{C}_4\text{--H}$ protons of the quinoline ring, respectively) exist exclusively in the enaminone form (B). The assignments of these doublets have already been reported by Mondelli and Merllini [9] (Scheme 3). However, for all azines which may have tautomeric forms (Scheme 2), these doublets did not appear. From these observations, we concluded that the compounds exist exclusively in the form 3-B. Obviously, substitution has effect on tautomeric ratio, but due to the limited number of samples we cannot draw a definite final conclusion. For comparison, ^1H NMR spectra of each category (**3b**, **3g** and **3l**) are presented in Figs. 1–3.

Some important ^{13}C NMR chemical shifts of the compounds studied are given in Table 2. These data show that there are signals around 38.8–39.7 and 94.0–100.0 ppm for the methylene and vinylic carbons, respectively. Low field signal at 158.9 ppm in the spectrum of compound **3b** which is found to be exclusively in the form B can be assigned to the quaternary carbon $\text{C}=\text{N}$. Moreover, the signal near 98.7 ppm can be attributed to the vinylic carbon atom. Since, no signal is detected around 38 ppm for the second tautomeric forms. Signals of the methylene carbons in the spectra of compounds **3a**, **3l** and **3m** were observed at 39.5 ppm. None of




Fig. 3. ^1H NMR spectrum of compound **3I** in deuteriochloroform solution.

the spectra for these compounds show the signal for the vinylic carbon around 98.5 ppm (the respective second tautomeric form is not present). Assignment of the above signals were confirmed by comparing the spectra with those of the DEPT spectra in which the signals are absent and the methylene signals are inverted. So, these observations show that the discussed compounds have only tautomeric form 3-A. On the other hand, the other (**3c–3k** and **3n–3s**) compounds exist as a mixture of tautomers which are proved by the presence of both methylene and vinylic signals observed around 39 and 99 ppm, respectively.

4. Conclusion

As it shown by IR, ^1H and ^{13}C NMR spectral data, tautomeric behavior of 2-ketomethylquinolineazines in chloroform solution depend on substitutions and in most of the samples studied two tautomeric forms are in equilibrium with each other, but in some cases one tautomer was dominate.

Acknowledgments

We thank the Department of Chemistry, University of Isfahan, Iran, for financial support and Professor Hasan Sabzyan for improving language of the article.

References

- [1] S. Radl, *Aldrichem. Acta* 30 (1997) 97–106.
- [2] A.I. Khodair, P. Bertrand, *Tetrahedron* 54 (1998) 4859–4872.
- [3] J. Jayabharathi, V. Thanikchalam, A. Thangamani, M. Padmavathy, *Med. Chem. Res.* 16 (2007) 266–279.
- [4] G.V. Kalayda, S. Komeda, T. Sato, M. Chikuma, J. Reedijk, *Eur. J. Inorg. Chem.* 24 (2003) 4347–4355.
- [5] (a) R. Cohen, B. Rybtchinski, M. Gandelman, L.J.W. Shimon, J.M.L. Martin, D. Milstein, *Angew. Chem. Int. Ed.* 42 (2003) 1949–1952; (b) S.G. Sreerama, S. Pal, *Inorg. Chem.* 44 (2005) 6299–6307; (c) C.Y. Wu, Y. Chen, C.S. Lee, J. Dinda, W.S. Hwang, *Polyhedron* 25 (2006) 3053–3065.
- [6] D.D. Choytun, L.D. Langlois, T.P. Johansson, C.L.B. Macdonald, G.W. Leach, N. Weinberg, J.A.C. Clyburnald, V.K. Srivastava, A. Kumar, *Chem. Commun.* (2004) 1842–1845.
- [7] R. Centore, C. Garzillo, *J. Chem. Soc., Perkin Trans. II* (1997) 79–84.
- [8] (a) N.N. Goldberg, R. Levine, *J. Chem. Soc., Perkin Trans. I* (1979) 2171–2179; (b) R.M. Acheson, G. Precter, *J. Am. Chem. Soc.* 73 (1951) 303–309; (c) R.M. Rousel, M.O. Deguerro, J. Galin, *Macromolecules* 19 (1986) 291–299; (d) J.V. Greenhill, H. Loghmani khouzani, *Tetrahedron* 44 (1988) 3319–3326; (e) H. Loghmani khouzani, M.M. Sadeghi, J. Safari, A. Minaeifar, *Tetrahedron Lett.* 42 (2001) 4363–4364; (f) J.W. Wolfe, D.E. Portlock, D.J. Feuerbach, *J. Org. Chem.* 39 (1974) 2006–2010.
- [9] R. Mondelli, L. Merllini, *Tetrahedron* 22 (1966) 3253–3273.
- [10] (a) J. V Greenhill, H. Loghmani khouzani, D.J. Maitland, *J. Chem. Soc., Perkin Trans. I* (1991) 2831–2840; (b) G. Fukata, C. O'Brien, R.A.M. O'Ferrall, *J. Chem. Soc., Perkin Trans. II* (1979) 792–795; (c) R. Gawincki, E. Kolehmainen, B. Osmialowski, P. Palkovic, M. Nissinen, *Heterocyclic Commun.* 5 (1999) 549–554; (d) E. Kolehmainen, B. Osmialowski, T.M. Krygowski, R. Kauppinen, M. Nissinen, R. Gawincki, *J. Chem. Soc., Perkin Trans. II* (2000) 1259–1266; (e) R. Gawincki, B. Osmialowski, E. Kolehmainen, M. Nissinen, *J. Mol. Struct.*

- 525 (2000) 233–239;
- (f) R. Gawincki, B. Osmialowski, E. Kolehmainen, R. Kauppinen, J. Physc. Org. Chem. 14 (2001) 201–204;
- (g) E. Kolehmainen, B. Osmialowski, M. Nissinen, R. Kauppinen, J. Gawincki, J. Chem. Soc., Perkin Trans. II (2000) 2185–2191;
- (h) R. Dobosz, E. Kolehmainen, B. Osmialowski, R. Gawincki, Tetrahedron 63 (2007) 9172–9178;
- (i) O. Martiskainen, R. Gawincki, B. Osmialowski, K. Wiinamäki, K. Pihlja, Rapid Commun. Mass Spectrom. 23 (2009) 1075–1084;
- (j) A.R.E. Carey, G. Fukata, R.A.M. O'Ferrall, M.G. Murphy, J. Chem. Soc., Perkin Trans. II (1985) 1711–1722.
- [11] R. Ranjbar-karimi, H. Loghmani khouzani, J. Iran. Chem. Soc. 8 (2011) 223–230.
- [12] E. Vinuelas-Zahions, F. Luna-Giles, P. Torres-Garcia, A. Bernalte-Garcia, Polyhedron 28 (2009) 4056–4064.
- [13] J.V. Greenhill, H. Loghmani khouzani, Specterochim. Acta 46A (1990) 803–808.